Amgen beats estimates thanks to strong 1st-qtr sales

29 April 2016

US biotech major Amgen (Nasdaq: AMGN) has beaten estimates and posted strong figures in its first quarter financial results for 2016.

The 7% growth in product sales, compared to the same period in 2015, is part of a 10% rise in total revenues which, combined with higher operating margins, has led to adjusted operating income of $2.86 billion and earnings per share (EPS) to reach $2.90, some 17% more than a year ago.

The EPS figure of $0.30 was ahead of Wall Street analysts’ predictions, according to Thomson Reuters, while the total revenue – at $5.53 billion – beats their estimates by more than $200 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK